Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Nutex Health, Inc. (IGMB)
|
Add to portfolio |
|
|
|
| Price: |
$4.77
| | Metrics |
| OS: |
661.9
|
M
| |
-412
|
% ROE
|
| Market cap: |
$3.16
|
B
| |
-12
|
% ROIC
|
|
Net debt:
|
$28.2
|
M
| |
|
|
|
EV:
|
$3.19
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($25.4)
|
M
| |
|
|
|
EBIT
|
($41.1)
|
M
| |
|
|
| EPS |
($0.68)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 219.3 | 18.8 | 1.6 | 1.4 | 1.4 | 0.0 | 0.0 | 0.3 |
| Revenue growth | 1066.8% | 1085.0% | 16.1% | 0.0% | 5800.9% | | -100.0% | |
| Cost of goods sold | 205.8 | 14.6 | 0.9 | 0.8 | 0.5 | 0.0 | 0.0 | -0.1 |
| Gross profit | 13.5 | 4.1 | 0.7 | 0.5 | 0.9 | 0.0 | 0.0 | 0.5 |
| Gross margin | 6.1% | 22.1% | 42.6% | 39.2% | 62.9% | -31.6% | | 139.8% |
| Selling, general and administrative | | | | | | | | 0.1 |
| Sales and marketing | | | | 0.6 | 0.2 | | | |
| Research and development | | 0.3 | 0.6 | 0.8 | 0.5 | | | |
| General and administrative | 18.0 | 12.2 | 3.3 | 3.7 | 0.9 | 1.8 | 0.4 | |
| EBITA | -4.6 | -8.3 | 4.9 | -4.6 | -0.8 | -5.2 | -0.4 | -0.5 |
| EBITA margin | -2.1% | -44.2% | 311.5% | -339.6% | -61.5% | -22269.9% | | -148.6% |
| Amortization of intangibles | | 0.7 | 0.1 | | | 0.5 | | |
| EBIT | -4.6 | -9.0 | 4.8 | -4.6 | -0.8 | -5.7 | -0.4 | -0.5 |
| EBIT margin | -2.1% | -48.0% | 305.5% | -339.6% | -61.5% | -24574.5% | | -148.6% |
| Pre-tax income | -419.6 | -14.7 | -5.5 | -7.1 | -1.0 | -6.0 | -0.5 | -0.5 |
| Income taxes | 13.1 | 1.0 | 0.0 | 0.0 | 0.0 | -6.6 | 7.0 | -0.6 |
| Tax rate | | | 0.0% | 0.0% | 0.0% | 109.7% | | 115.4% |
| Earnings from continuing ops | -424.8 | -13.7 | -5.7 | -7.1 | -1.0 | -6.0 | -0.5 | 0.1 |
| Earnings from discontinued ops | | | | | | 6.6 | -7.0 | 0.6 |
| Net income | -424.8 | -13.7 | -5.7 | -7.1 | -1.0 | 0.6 | -7.4 | 0.1 |
| Net margin | -193.7% | -72.7% | -356.3% | -520.8% | -69.5% | 2512.6% | | 25.1% |
| |
| Diluted EPS | ($0.67) | ($0.37) | ($1.14) | ($1.96) | ($0.56) | ($0.07) | ($0.01) | $0.00 |
| Shares outstanding (diluted) | 634.0 | 36.9 | 5.0 | 3.6 | 1.7 | 83.7 | 39.7 | 29.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|